ABT-737 化学構造
分子量: 813.43

高品質保証

文献中の引用(85)

カスタマーフィードバック(14)

Quality Control & MSDS

製品説明

  • Compare Bcl-2 Inhibitors
    Bcl-2製品生物活性の比較
  • 研究分野
  • Combination Therapy
    併用療法
  • ABT-737のメカニズム

製品の説明

生物活性

製品説明 ABT-737は、Bcl-xL、Bcl-2とBcl-wのBH3模倣の阻害剤で、EC50 がそれぞれ78.7 nM、30.3 nM 、197.8 nMになる。
ターゲット

Bcl-xL

Bcl-2

Bcl-w

IC50

78.7 nM (EC50)

30.3 nM (EC50)

197.8 nM (EC50) [1]

In vitro試験 ABT-737 shows low activity to Bcl-B and no effects to Mcl-1 and BFL-1. ABT-737 is sensitive to HL60, KG1 and NB4 cells with IC50 of 50 nM, 80 nM and 80 nM, respectively. ABT-737 induces apoptosis in HL60 cells, which due to decreased Bcl-2/Bax heterodimerization and has no effect on cell cycle distribution. ABT-737 also induces cytochrome c release from purified mitochondria and promotes conformational changes in Bax that are associated with apoptosis. [1] Resistant cells (Hela and MCF-7) can be sensitized to ABT-737 by approaches that down-regulate, destabilize, or inactivate Mcl-1. ABT-737 also causes Bax/BAK-dependent cytochrome c release only when Mcl-1 has been neutralized. [2] ABT-737 displaces Bim from Bcl2's BH3-binding pocket, allowing Bim to activate Bax, induce mitochondrial permeabilization, and rapidly commit the primary chronic lymphocytic leukemia (CLL) cells to death. [3] Knockdown of Mcl-1 with siRNA sensitizes two resistant SCLC cell lines H196 and DMS114 to ABT-737 by enhancing the induction of apoptosis. Likewise, up-regulation of Noxa sensitizes H196 cells to ABT-737. ABT-737 inhibits proliferation and induces apoptosis in many SCLC cell lines including NCI-H889, NCI-H1963, NCI-H1417, NCI-H146 and etc. Bcl-2 and Noxa may contribute mechanistically to the cellular response to ABT-737 in NCI-H146 cells. [4] A recent study shows that ABT-737 significantly induces apoptosis in HTLV-1 infected T-cell lines as well as in fresh ATLL cells. [5]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
OCI-Ly1  MUHD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NVzZ[4R5OjVyIH7NxsA> Mo\BO|IhcA>? NVz0SVZGTE2VTx?= MWfjZZV{\WRiOUelJIxwe3Nib3[geoli[mmuaYT5JIlvKGOnbHzzJJRz[W6|ZnXjeIVlKHerdHigRmNNPiC|aWLORS=> NFHud5AzPjZ3N{K4PC=>
KG1a NH;XdoFE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M3PKZVAuOTBizszN NILPPJQzPCCq M37CN2ROW09? MXLJR|UxRTdwNkig{txONCCmZXPy[YF{\XNiY3XscEB3cWGkaXzpeJkhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NUTlWIhDOjZ3NUK3NVI>
Kasumi-1 MmjkR4VtdCCYaXHibYxqfHliQYPzZZk> NIjOXXYxNTFyIN88US=> MUKyOEBp MX\EUXNQ M4q2TWlEPTB;ND64O{DPxE1uIHTlZ5Jm[XOnczDj[YxtKH[rYXLpcIl1gSCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? M374cVI3PTV{N{Gy
KG1a MWPBdI9xfG:|aYOgRZN{[Xl? NVzQTnR4OC1zMDFOwG0> NWrV[pFNOjRiaB?= NIjubpZFVVOR NFjIRWhqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NXzteZRNOjZ3NUK3NVI>
Kasumi-1 MkDERZBweHSxc3nzJGF{e2G7 M1rFU|AuOTBizszN NGHQfpYzPCCq NXj2XlhtTE2VTx?= MX3pcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NILRR3IzPjV3MkexNi=>
MC-3  M{Wwb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWjrV2xpPS9zMD:yNEDPxE1? NXvUWGpjOjRiaB?= MmPzSG1UVw>? MoTPbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NYC1OZY6OjZ2NEe2NVU>
HN22  MluwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFX5NnUzNjVxNz61M|IzNjVizszN MlTGNlQhcA>? NEi2[pNFVVOR NInWNIRqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? M1r3VVI3PDR5NkG1
MC-3  M1vMRWFxd3C2b4Ppd{BCe3OjeR?= MXG1M|ExNzJyIN88US=> MkjYNlQhcA>? NVLhOnRRTE2VTx?= MoXObY5lfWOnczDjZZNx[XOnLX3l[IlifGWmIHHwc5B1d3Orcx?= NHK5O5UzPjR2N{[xOS=>
HN22  NID5V5dCeG:ydH;zbZMhSXO|YYm= MnLZNk42NzdwNT:yNk42KM7:TR?= NGDZSG8zPCCq M2niWmROW09? MXPpcoR2[2W|IHPhd5Bie2VvbXXkbYF1\WRiYYDvdJRwe2m| Mmf6NlY1PDd4MUW=
MOLT-4 M1XSbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWf1ZXNtOTBvNUCwNEBvVQ>? Mn6xO|IhcA>? M1;XWGROW09? NVy2XVk{UUN3ME2wMlE6QCEQvF2= NWLOZmlUOjZ|OUKzN|I>
RS4;11 M3jBNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2HIZVExNTVyMECgcm0> MkfRO|IhcA>? NVjpXmI2TE2VTx?= NVPlNnhKUUN3ME2wMlAxOiEQvF2= MkHLNlY{QTJ|M{K=
JURKAT NVrV[HNNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn;LNVAuPTByMDDuUS=> NWPYWVdWPzJiaB?= NF2wR3FFVVOR NYTK[GVKUUN3ME22OkDPxE1? MXyyOlM6OjN|Mh?=
CEM R MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVfNUIdZOTBvNUCwNEBvVQ>? MnPKO|IhcA>? NFv1RnVFVVOR MlS0TWM2OD13LkSg{txO NUX6eWV6OjZ|OUKzN|I>
CEM S MkLzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFvnfVMyOC13MECwJI5O NH3CV5k4OiCq MYPEUXNQ MV;JR|UxRTF{LkGg{txO MXKyOlM6OjN|Mh?=
MOLT-4 Ml;sRZBweHSxc3nzJGF{e2G7 M3HMeVExNTFyMECgcm0> M{fvWlI1KGh? MlzWSG1UVw>? NY\Gempu[2G3c3XzJJRp\SClbHXheoFo\SCxZjDCZ4wuOiCjbnSgeIhmKGSxd37y[Yd2dGG2aX;uJI9nKEKlbD34UEBidmRiTXPsMVE> Ml\3NlY{QTJ|M{K=
CEM S NGKx[4FCeG:ydH;zbZMhSXO|YYm= MX6xNE0yODByIH7N NFXKUIYzPCCq NVriRnR4TE2VTx?= MnXJZ4F2e2W|IITo[UBkdGWjdnHn[UBw\iCEY3ytNkBidmRidHjlJIRwf26{ZXf1cIF1cW:wIH;mJGJkdC26TDDhcoQhVWOuLUG= MnnLNlY{QTJ|M{K=
JURKAT NYnkNG9rT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXrvWIQxOTByLUGwNFAhdk1? NVLLVGtlPDhiaB?= NXvFOGxnTE2VTx?= NH3zTphKSzVyPUm1OeKyQS5|IH7N Moq5NlYyPzJ{Nkm=
LOUCY MoGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIOzbGkyODBvMUCwNEBvVQ>? NX\jRWZbPDhiaB?= Mn\SSG1UVw>? MoW3TWM2OD1|Mj64xtEyOC57IH7N Mo[xNlYyPzJ{Nkm=
WM-115 MXnD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MoH0NVAxyqCwTR?= Mny5O|IhcA>? NH2wVHdmdmijbnPld{BkfXKldX3pck1qdmS3Y3XkJIFvfGlvc4Xyeol3[W{EoB?= MXOyOlEyPjd5Nh?=
B16 NYGxTZpNS2WubDDWbYFjcWyrdImgRZN{[Xl? NXPYe2NmOTBywrDuUS=> NE\Nc4g4OiCq Mnvk[Y5p[W6lZYOgZ5Vz[3WvaX6tbY5lfWOnZDDhcpRqNXO3co\peoFtyqB? NXyzfpY3OjZzMU[3O|Y>
HL-60  NXfaWY1sT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml3DO|IhcA>? MkD6TWM2OMLiPTCxNE44KG6P MUWyOlA1PTZyOR?=
MOLM-13  NGC0WIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIr5TZU4OiCq M4HaXGlEPTEEoE2gNlcvQSCwTR?= NH3PeokzPjB2NU[wPS=>
OCI-AML3 NVW5UoI5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4XGTVczKGh? M2WwZ2lEPTEEoE2gNVk2OCCwTR?= NXvQ[Y9wOjZyNEW2NFk>
BCWM.1 MVfBdI9xfG:|aYOgRZN{[Xl? M{LmdFAuOS54IN88US=> MViyOEBp NYTTSnNzcW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= NIXC[IszPTh7M{K5NC=>
MWCL-1 M4rhV2Fxd3C2b4Ppd{BCe3OjeR?= NISxeY0xNTFwNjFOwG0> MU[yOEBp MVHpcoR2[2W|IHPlcIwh[XCxcITvd4l{ M4fTWVI2QDl|Mkmw
MM.1s NIHUbHpCeG:ydH;zbZMhSXO|YYm= NHnyemkxNTFwNjFOwG0> NUWyUoRiOjRiaB?= MofobY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? NInuOpMzPTh7M{K5NC=>
HCT116 M2OzXGZ2dmO2aX;uJGF{e2G7 MoLBN{8yOCEQvF2= MojKNVLDqGkEoB?= M33wUGROW09? NX;QSYFCcW6mdXPld{BiKGSxc3Wt[IVx\W6mZX70JIlv[3KnYYPlJIlvKEyFM1KtTWkh[2:wdnXyd4lwdiCjbnSgV3FUXE1zIHTl[5Ji\GG2aX;u MVuyOVcyPTB{OB?=
HCT116 BAX BAK1 DKO MULGeY5kfGmxbjDBd5NigQ>? NV25eHlmOy9zMDFOwG0> NWG4SmJ[OTMEoHlCpC=> NHzURpJFVVOR MnHMbY5lfWOnczDhJIRwe2VvZHXw[Y5l\W62IHnuZ5Jm[XOnIHnuJGxEO0JvSVmgZ49vfmW{c3nvckBidmRiU2HTWG0yKGSnZ4Lh[IF1cW:w NX;QcJVROjV5MUWwNlg>
HCT116 MkjmSpVv[3Srb36gRZN{[Xl? NELm[3QyOCEQvF2= Mo[4NVLDqGkEoB?= M1r0SGROW09? NVHsRXFncW6lcnXhd4V{KEeIUD3MR|NDKHC3bnP0ZS=> NVLLXZFPOjV5MUWwNlg>
HCT116 BAX BAK1 DKO NYDGZnVvTnWwY4Tpc44hSXO|YYm= NH;tS4syOCEQvF2= MnjmNVLDqGkEoB?= NEXH[2RFVVOR MoDtbY5kemWjc3XzJGdHWC2OQ{PCJJB2dmO2YR?= MXyyOVcyPTB{OB?=
HCT116 MVLBeZRweGijZ4mgRZN{[Xl? MnXWNVAh|ryP NX;lPJk5OTMEoHlCpC=> MmnXSG1UVw>? NF\5eYhqdmS3Y3XzJIEh[2:vcHzleIUh[XW2b4DoZYdq[yC{ZYPwc45{\Q>? NUix[2RnOjV5MUWwNlg>
HCT116 BAX BAK1 DKO M3vlN2F2fG:yaHHnfUBCe3OjeR?= MYCxNEDPxE1? M{KwOFEzyqCqwrC= MVfEUXNQ NXnHVG96cW6mdXPld{BiKGOxbYDs[ZRmKGG3dH;wbIFocWNicnXzdI9ve2V? MoPvNlU4OTVyMki=
U937 NFL6dHFCeG:ydH;zbZMhSXO|YYm= NILDVXAxNjF{NT2yJO69VQ>? NH3tVFYzPCCq MXzlcohidmOnczDETGEwYC1zMT3pcoR2[2WmIHHwc5B1d3Orcx?= MlXNNlU4OTRyMkS=
U937  NHPuUGZCeG:ydH;zbZMhSXO|YYm= MXWwMlUh|ryP MV[yOEBp NGG1WJZmdmijbnPld{BkdGWjdnHn[UBw\iCSQWLQJIFv\CClYYPwZZNmNTNiYYOge4VtdCCjczDOc5hiKGyndnXs NUfFSIxIOjV5MUSwNlQ>
HL-60 AAA-Bcl-2 MVTBdI9xfG:|aYOgRZN{[Xl? NFn5[lkxNTVizszN MonKOFghcA>? NHS3VG1KSzVyPUCuPFch|ryv78{MbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NIi2cZEzPTdzMUS2NC=>
HL-60 EEE-Bcl-2 NGnpW3FCeG:ydH;zbZMhSXO|YYm= MX[wMVUh|ryP M3\0NlQ5KGh? MV\JR|UxRTVizszt89yNKGmwZIXj[ZMh[2WubDDhdI9xfG:|aYOgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NF[1WIszPTdzMUS2NC=>
U87 NFWzeZRHfW6ldHnvckBCe3OjeR?= M{TFS|UxKM7:TR?= M2T3VVI1KGh? NXrPbWlxemWmdXPld{B1cGVibWLORUBmgHC{ZYPzbY9vKGyndnXsd{Bw\iCPTWCtNkwhVU2SLUG0JIFv\CCEY3ytNi=> MoroNlU3Pjd4NkO=
K562 NFrX[lRE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M1rzWFEuOTBizszN NWrGS|dTPDhiaB?= MoD4SG1UVw>? NGrUcIFKSzVyPUK2Mlch|ryP MXeyOVU6PjV4MR?=
K562/Mcl -1-IRESBim NGj4TmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU[5NFNNUUN3ME25MlMh|ryP NH71PIQzPTV|NUmwNC=>
K562/Bcl- 2-IRESBim MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHPZOVVKSzVyPUCuN|Uh|ryP NEi5e|czPTV|NUmwNC=>
Jurkat M4Pjb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTBwNk[g{txO MXyyOVU{PTlyMB?=
JurkatΔBak NUe2Rm1GT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWLNTIlLUUN3ME61NEDPxE1? MWiyOVU{PTlyMB?=
HL60/VCR MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRjFyMDFOwG0> MWKyOVU{PTlyMB?=
Kasumi-1 M3nzOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRTBwMEGg{txO MmCzNlU2OzV7MEC=
Kasumi-1/ABT NInQTIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2rpcWlEPTB;MD61NUDPxE1? M3z0[FI2PTN3OUCw
THP-1 NXHybXBbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVzkcld2UUN3ME2xMlI4KM7:TR?= MWeyOVU{PTlyMB?=
U937 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3WxbWlEPTB;NT6yPUDPxE1? NIrLdYMzPTV|NUmwNC=>
C1498 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\2Z2lEPTB;Nj6xN{DPxE1? M3r0fVI2PTN3OUCw
RPMI 8226 NX\LRnQzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MonxTWM2OD1yLkK1JO69VQ>? M2jFUVI2PTN3OUCw
MM.1S NXvhVIF4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFXlNYdKSzVyPUCuOFAh|ryP M3[xNVI2PTN3OUCw
NCI-H929 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2\hPGlEPTB;MUWuNlEh|ryP NUPsTFVVOjV3M{W5NFA>
U266 M4TH[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljITWM2OD1yLk[4JO69VQ>? NWD0TVl5OjV3M{W5NFA>
MCF-7 MoPKR4VtdCCYaXHibYxqfHliQYPzZZk> MmnpOUDPxE1? MmL2OFghcA>? M{PDOGROW09? Mmnm[Y5p[W6lZYOgeIhmKHOnboPpeIl3cXS7IITvJI9zKHKjZHnheIlwdg>? NF34bI4zPTRyOUGyOC=>
MCF-7 M2XMcGFxd3C2b4Ppd{BCe3OjeR?= NXrW[4NlPSEQvF2= MXK0M|I1NzR6IHi= NXXjcWoxTE2VTx?= MmPWbY5kemWjc3XzJJRp\SClbHXheoVlKFCDUmC= MXGyOVQxQTF{NB?=
MCF-7 MnX6SpVv[3Srb36gRZN{[Xl? Mnn6OUDPxE1? M{OwUFI1KGh? NVznS4lPTE2VTx?= NWXWUXl7\W6qYX7j[ZMhfGinbHX2[Ywhd2ZiTXPsMVEh\XiycnXzd4lwdsLi NXfDTZdTOjV2MEmxNlQ>
MDA-MB 231  NGPIc5dHfW6ldHnvckBCe3OjeR?= MknyOUDPxE1? MV:yOEBp NWKyfXNKTE2VTx?= M2LlboVvcGGwY3XzJJRp\WyndnXsJI9nKE2lbD2xJIV5eHKnc4Ppc47DqA>? NVfSVZU{OjV2MEmxNlQ>
ZR-75-1  NGnYV2JHfW6ldHnvckBCe3OjeR?= NFfYT2M2KM7:TR?= NYToOnpvOjRiaB?= NXn0VGNKTE2VTx?= M3i3eoVvcGGwY3XzJJRp\WyndnXsJI9nKE2lbD2xJIV5eHKnc4Ppc47DqA>? M4HvUFI2PDB7MUK0
A549 MV;D[YxtKF[rYXLpcIl1gSCDc4PhfS=> NFyxclkxNTJyIN88US=> MVm3NkBp M365eWROW09? Mn3C[IVkemWjc3XzJJRp\SClZXzsJJN2en[rdnHsJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXyJINwdWKrbnXkJJdqfGhiYYPwbZJqdg>? MlriNlU{QDh5NkK=
H1299 MWXD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MWCwMVIxKM7:TR?= NV3zR4x4PzJiaB?= NWPXbIJUTE2VTx?= NVzuPWRX\GWlcnXhd4V{KHSqZTDj[YxtKHO3co\peoFtKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVzKGOxbXLpcoVlKHerdHigZZNxcXKrbh?= NEj1eI0zPTN6OEe2Ni=>
HO-8910 Mnq0R4VtdCCYaXHibYxqfHliQYPzZZk> MUGwMVIxKM7:TR?= NFy2fXk4OiCq NF;IXlVFVVOR NXTVTZVQ\GWlcnXhd4V{KHSqZTDj[YxtKHO3co\peoFtKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVzKGOxbXLpcoVlKHerdHigZZNxcXKrbh?= Mn3sNlU{QDh5NkK=
HT-29 MVnD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NHzMd3MxNTJyIN88US=> NXvLS28zPzJiaB?= NXPWU|g2TE2VTx?= NYL6[ZFn\GWlcnXhd4V{KHSqZTDj[YxtKHO3co\peoFtKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVzKGOxbXLpcoVlKHerdHigZZNxcXKrbh?= MkKxNlU{QDh5NkK=
HCT-116 NH7EdpJE\WyuIG\pZYJqdGm2eTDBd5NigQ>? Ml\UNE0zOCEQvF2= MWq3NkBp MVLEUXNQ MlXC[IVkemWjc3XzJJRp\SClZXzsJJN2en[rdnHsJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXyJINwdWKrbnXkJJdqfGhiYYPwbZJqdg>? MYWyOVM5QDd4Mh?=
A549 MWnBdI9xfG:|aYOgRZN{[Xl? MWCyNEDPxE1? NUnqdohwPDhiaB?= MnrGSG1UVw>? M1LxfYlv\HWlZYOgZZBweHSxc3nzJJNq\26rZnnjZY51dHliY3;tZolv\WRid3n0bEBie3Crcnnu MkLLNlU{QDh5NkK=
H1299 Mon1RZBweHSxc3nzJGF{e2G7 NHn6fGkzOCEQvF2= NFLMUVc1QCCq NVjkeXF1TE2VTx?= M1HNN4lv\HWlZYOgZZBweHSxc3nzJJNq\26rZnnjZY51dHliY3;tZolv\WRid3n0bEBie3Crcnnu MoLiNlU{QDh5NkK=
Sc-1 NGfIdVlE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MYKwMlAxODFvMTFOwG0> NIq1UVQ6PiCq MoW3[IVkemWjc3XzJJRp\SClZXzsJJZq[WKrbHn0fUBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NXTpcYdwOjV|N{O1NFg>
OcI-LY18 MlqxR4VtdCCYaXHibYxqfHliQYPzZZk> NIjJe44xNjByMEGtNUDPxE1? M1zJbVk3KGh? MXLk[YNz\WG|ZYOgeIhmKGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MWKyOVM4OzVyOB?=
RL  M3HZOWNmdGxiVnnhZoltcXS7IFHzd4F6 M3;0blAvODByMT2xJO69VQ>? NHfweVQ6PiCq MWjk[YNz\WG|ZYOgeIhmKGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy M1fvblI2Ozd|NUC4
RKO NGfMO5hE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NWDBfYZHOC1zMDFOwG0> NVm1T4VNOjUkgJnoxsA> MnzPSG1UVw>? NYLreXVbUUN3ME9ihKkzPeLCidM1US=> NY[zb5hPOjV|MESzPFM>
Caco-2 Ml\WR4VtdCCYaXHibYxqfHliQYPzZZk> NEDWRYoxNTFyIN88US=> MlLUNlTjiImqwrC= NIHIeZdFVVOR MlXTTWM2OD1zOT635qCKyrWP MXyyOVMxPDN6Mx?=
DLD1 Mn3rR4VtdCCYaXHibYxqfHliQYPzZZk> NUHKeIxJOC1zMDFOwG0> MlnxNlTjiImqwrC= MVPEUXNQ NXPYXGQ2UUN3ME2xPE44QOLCidM1US=> NIPtR2czPTNyNEO4Ny=>
LS411N M{nTXmNmdGxiVnnhZoltcXS7IFHzd4F6 Ml\3NE0yOCEQvF2= Mn\BNlTjiImqwrC= NUPKOnN{TE2VTx?= MUXJR|UxRTFzLkS35qCKyrWP MYCyOVMxPDN6Mx?=
SW620 NYLRU2JSS2WubDDWbYFjcWyrdImgRZN{[Xl? MkDONE0yOCEQvF2= NHPRVY4zPOLCiXlCpC=> MnzZSG1UVw>? NGTWVG9KSzVyPUGyMlI16oDLwsXN NWnENGNGOjV|MESzPFM>
HCT116 M1jxUmNmdGxiVnnhZoltcXS7IFHzd4F6 MmjENE0yOCEQvF2= MV2yOQKBkWkEoB?= MmPwSG1UVw>? MlXFTWM2OD1{MD60PgKBkcL3TR?= MVSyOVMxPDN6Mx?=
HaCaT MkPiR4VtdCCYaXHibYxqfHliQYPzZZk> Mkn1NE4yNzFxMUCg{txO NVXiUVF1OjRiaB?= MV3EUXNQ NYnPfWZ[\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MXuyOVIyODd7NR?=
A5-RT3 MWTD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NFPL[YcxNjFxMT:xNEDPxE1? NIOyTlUzPCCq MUDEUXNQ MVzk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MX2yOVIyODd7NR?=
HaCaT M1rtfmZ2dmO2aX;uJGF{e2G7 MUGxNQKBkc7:TR?= M4L5OlI1NzR6IHi= MYfEUXNQ MlnHbY5lfWOnczDNUXAh[W6mIFTORUBnemGpbXXueIF1cW:w Ml7jNlUzOTB5OUW=
A5-RT3 Mn3iSpVv[3Srb36gRZN{[Xl? MnW5NVDjiIoQvF2= MkHsNlQwPDhiaB?= M{\4NGROW09? M1juWIlv\HWlZYOgUW1RKGGwZDDEUmEh\nKjZ33lcpRifGmxbh?= M4Pk[|I2OjFyN{m1
A5-RT3 NELZTYdHfW6ldHnvckBCe3OjeR?= NWLJcZduPSEQvF2= NHjCS5c3KGh? MXTEUXNQ NWPBdW1XcW6mdXPld{B1cGVicnXs[YF{\SCxZjDtbZRw[2ixbnTybYFtKHC{b4TlbY5{KGGwZDDy[YR2[2W|IHPsc45w\2WwaXOgd5Vzfmm4YXygbY4h[SClYYPwZZNmNWmwZHXw[Y5l\W62IH3hco5meg>? MVOyOVIyODd7NR?=
U266 M1XGZmZ2dmO2aX;uJGF{e2G7 NF7HTWo2ODBxN{WwJI5O M2\ofVI1NzR6IHi= NIn0UmlFVVOR NV;3NG9k\G:5boLl[5Vt[XSnczDCbY0tKHC{aX7jbZBidGy7IITo[UBGVCCrc3;mc5Ju NEHZSmczPTJyOEi4PC=>
RPMI8226 MWrGeY5kfGmxbjDBd5NigQ>? NHmxfo02ODBxN{WwJI5O MXSyOE81QCCq M4Gx[mROW09? MnHY[I94dnKnZ4XsZZRmeyCEaX2sJJBzcW6laYDhcIx6KHSqZTDFUEBqe2:ob4Lt NYjTcZlTOjV{MEi4PFg>
MM.1S MUPGeY5kfGmxbjDBd5NigQ>? NELFfXo2ODBxN{WwJI5O MWeyOE81QCCq MUHEUXNQ M3jJOIRwf26{ZXf1cIF1\XNiQnntMEBxemmwY3nwZYxtgSC2aHWgSWwhcXOxZn;ycS=> MnjZNlUzODh6OEi=
Clone A NVzZRY9{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGT4W3YxNjMkgKO2NEDPxE1? MlXLO|IhcA>? MYDEUXNQ M1;TVWlEPTB;Nz61JO69VQ>? NFrjTIEzPTJyOEi4Ni=>
CX-1 NIrWRZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkfTNE4z6oDVNkCg{txO NYDnXWdkPzJiaB?= MXvEUXNQ Mn3NTWM2OD1zLkig{txO NIH0bYwzPTJyOEi4Ni=>
LS174T M2LFWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEfhdHkxNjMkgKO2NEDPxE1? NFWxSYE4OiCq M{PJTGROW09? NWXYO|BSUUN3ME2xPE4{KM7:TR?= MUeyOVIxQDh6Mh?=
HT29 NHHy[IFCeG:ydH;zbZMhSXO|YYm= NUPnTFlqOS93L{GwJO69VQ>? NHXqXYQ1QCCq M2mx[4NifXOnczDj[YxtKGSnYYToJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NHPJbmYzPTF7MkG4PC=>
SW480 NGXrUGlCeG:ydH;zbZMhSXO|YYm= NWK4bmE{OS93L{GwJO69VQ>? M4DkdlQ5KGh? MoLwZ4F2e2W|IHPlcIwh\GWjdHigbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NY\5e285OjVzOUKxPFg>
Colo205 MkGzRZBweHSxc3nzJGF{e2G7 M4LBdVEwPS9zMDFOwG0> MUm0PEBp NUP5NWxU[2G3c3XzJINmdGxiZHXheIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> M3fFeVI2OTl{MUi4
Caco2 MYTBdI9xfG:|aYOgRZN{[Xl? NHToNpMyNzVxMUCg{txO NF;JXnc1QCCq MX\jZZV{\XNiY3XscEBl\WG2aDDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= Mn7CNlUyQTJzOEi=
PCI-13 Moe0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXS3NkBp MYLEUXNQ MkXhS2k2OD1zNTFCtUAyNjhizszN M4rVUVI2OTN7M{i3
PCI-15B NGezTXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVPyeIpWPzJiaB?= MnXxSG1UVw>? MXzHTVUxRTFzINMxJFQvPSEQvF2= NFf3V3QzPTF|OUO4Oy=>
UM-SCC22B M3v2Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGfzfYU4OiCq MXfEUXNQ NYD3fIZDT0l3ME2xPUDDuSB{Lkmg{txO NF7nUJkzPTF|OUO4Oy=>
UM-SCC47 M1n5TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHzpRo44OiCq NUjxTHdtTE2VTx?= MUHHTVUxRTF7INMxJFEzNjNizszN MojYNlUyOzl|OEe=
93-VU-147T M3HleGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVe3NkBp NGPrPIxFVVOR NGnYZmJIUTVyPUSuN{DDuSB|LkWg{txO M{jweFI2OTN7M{i3
UD-SCC2 M3TmUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3jZblczKGh? NITJN3JFVVOR MlvPS2k2OD1{ODFCtUAzNjlizszN NGK2NHIzPTF|OUO4Oy=>
UPCI:SCC90 M{XWeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVu3NkBp NV;ENGFTTE2VTx?= MnT4S2k2OD14Lk[gxtEhOS53IN88US=> M1noWVI2OTN7M{i3
RPMI-8226  MkD1R4VtdCCYaXHibYxqfHliQYPzZZk> M3zHTlEzPS9{NUCvOVAxKG6P M1\JUFQ5cMLi NGnmRodFVVOR MYTk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MX2yOVAxQDJyMh?=
OPM-2  NH:yNpZE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NYHySnFwOTJ3L{K1NE82ODBibl2= NYHmTWYxPDiqwrC= MX3EUXNQ Ml3r[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NYG2cZZMOjVyMEiyNFI>
RPMI-8226  MnLwRZBweHSxc3nzJGF{e2G7 NGniR28yOjVxMkWwM|UxOCCwTR?= M{n1S|Q5cMLi MXHEUXNQ MkDjbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? M2TJc|I2ODB6MkCy
OPM-2  NHvPVXFCeG:ydH;zbZMhSXO|YYm= MUOxNlUwOjVyL{WwNEBvVQ>? Mn;LOFhpyqB? M4q5TWROW09? MX;pcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz M{HLOVI2ODB6MkCy
COG-LL-319 Mmr3SpVv[3Srb36gRZN{[Xl? NIXDb24yODBibl2= M1noXFEwOy94IHi= M{LGd2ROW09? NULwXolHcW6mdXPld{Bk[XOyYYPlMYRmeGWwZHXueEBO[2xvMTDjcIVifmGpZR?= MoDENlQ6PTF2N{K=
RS4;11 M2Tvd2Z2dmO2aX;uJGF{e2G7 NXTMdWdKOTByIH7N M2f6d|EwOy94IHi= MnOzSG1UVw>? MUjpcoR2[2W|IHPhd5Bie2VvZHXw[Y5l\W62IF3jcE0yKGOuZXH2ZYdm NGntVo4zPDl3MUS3Ni=>

... Click to View More Cell Line Experimental Data

In vivo試験 In aggressive leukemia model, ABT-737 suppresses the leukemia burden by 53% at the 30 mg/kg, with significantly extended survival of mice. ABT-737 does not induce significantly abnormalities in blood cell counts or serum chemistries. [1] ABT-737 prolongs the survival of recipient mice transplanted with Bcl-2-transduced tumors. [2] ABT-737 shows great antitumor activity in an ATLL mouse model at a dose of 100 mg/kg. [5]
臨床試験 ABT-737, associated with Platinum, is currently under Phase II clinical trials in ovarian tumors.
特集 First-generation inhibitor of anti-apoptotic Bcl-2 proteins.

プロトコル (参考用のみ)

キナーゼアッセイ:

[1]

Fluorescence polarization assays Binding affinity of GST-Bcl-2 family proteins to the FITC-conjugated BH3 domain of Bim (FITC-Ahx-DMRPEIWIAQELRRIGDEFNAYYAR) is determined. Briefly, 100 nM of GST-Bcl-2 family fusion proteins are incubated with serial dilutions of ABT-737 in PBS for 2 min. Then, 20 nM of FITC-Bim BH3 peptide (FITC-Ahx-DMRPEIWIAQELRRIGDEFNAYYAR) is added. Fluorescence polarization is measured using an Analyst TM AD Assay Detection System after 10 min using the 96-well black plate. Then IC50 are determined.

細胞アッセイ:

[4]

細胞株 SCLC cell lines NCI-H889, NCI-H1963, NCI-H1417, NCI-H146, NCI-187, DMS79, NCI-1048, NCI-H82, NCI-H196, H69AR, and DMS114
濃度 0.001-10 μM
反応時間 48 hours
実験の流れ

SCLC cells are treated for 48 hours in 96-well tissue culture plates in a total volume of 100 μL tissue culture medium supplemented with 10% human serum. Viable cells are determined using the MTS assay.

動物実験:

[1]

動物モデル Scid mice injected with Luc-expressing FD/ΔRaf-1:ER cells
製剤 1 g/mL stock solution of ABT-737 in DMSO is added to a mixture of 30% propylene glycol, 5% Tween 80, 65% D5W (5% dextrose in water) (pH 4−5; final concentration of DMSO ≤ 1%)
投薬量 20 and 30 mg/kg
投与方法 For intraperitoneal (i.p.) every day

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDogMonkeyBaboon
Weight (kg)0.020.151.80.40.0810312
Body Surface Area (m2)0.0070.0250.150.050.020.50.240.6
Km factor361285201220
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

参考

化学情報

Download ABT-737 SDF
分子量 813.43
化学式

C42H45ClN6O5S2

CAS No. 852808-04-9
保管 2年-20℃
6月-80℃in solvent
別名 N/A
溶解度 (25°C) * In vitro DMSO 100 mg/mL (122.93 mM)
<1 mg/mL (<1 mM)
エタノール <1 mg/mL (<1 mM)
In vivo 30% Propylene glycol, 5% Tween 80, 65% D5W 30mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
化学名 Benzamide, 4-[4-[(4'-chloro[1,1'-biphenyl]-2-yl)methyl]-1-piperazinyl]-N-[[4-[[(1R)-3-(dimethylamino)-1-[(phenylthio)methyl]propyl]amino]-3-nitrophenyl]sulfonyl]-

カスタマーフィードバック (14)


Click to enlarge
Rating
Source Nat Med, 2013, 19(11), 1478-88. ABT-737 purchased from Selleck
Method Western blot
Cell Lines MCF-7 cells
Concentrations 0/0.1/1/10 uM
Incubation Time 12 h
Results Mst1 inhibition of autophagy was dose-dependently reversed by treatment with ABT-737.

Click to enlarge
Rating
Source J Clin Invest, 2011, 121, 1053-1063. ABT-737 purchased from Selleck
Method Apoptosis assays
Cell Lines PMNs
Concentrations 1-10 μM
Incubation Time 20 h
Results ABT-737 completely abrogated the enhanced survival of neutrophils under hypoxia at a concentration that also reversed the survival effect of GM-CSF, a pro-survival stimulus known to induce BCL-XL but was without effect upon constitutive apoptosis.

Click to enlarge
Rating
Source Blood, 2011, 17(26), 7145-54. ABT-737 purchased from Selleck
Method Immunohistochemistry
Cell Lines Platelets
Concentrations 100nM
Incubation Time 2 h
Results There has been considerable discussion on the involvement of apoptotic signaling events in platelet activation. Therefore, we investigated apoptosis pathways after exposure to platelet agonists or BCL2 inhibition. Exposure to ABT-737 induced release of TMRE, and caspase cleavage, in agreement with activation of the intrinsic apoptotic pathway.

Click to enlarge
Rating
Source Blood, 2011, 17(26), 7145-54. ABT-737 purchased from Selleck
Method Immunohistochemistry
Cell Lines Platelets
Concentrations 100nM
Incubation Time 2 h
Results Further characterization of the ABT-737-induced cytoskeletal changes was performed on glass coverslips, which induced a spontaneous activation and spreading of the control platelets but not of ABT-737-treated platelets. Activated control platelets displayed a tubulin ring close to the cell center with actin fibers surrounding it. After exposure to ABT-737, a marked condensation of actin structures and inhibition of tubulin ring formation were observed in those cells that were apoptotic.

Click to enlarge
Rating
Source Cell death dis, 2013, 4, e801. ABT-737 purchased from Selleck
Method Flow cytometry
Cell Lines SW480, SW620
Concentrations 1 uM
Incubation Time 24 h, 48 h , 72 h
Results a)adherent SW480 cells were totally resistant to ABT-737 (1 uM). However, in suspended cells, the presence of ABT-737 was found to greatly increase the level of anoikis. (b)The same type of experiments were performed in SW620 cells. Again, adherent cells were resistant to ABT-737.Surprisingly, SW620 cells cultured in suspension, despite their resistance to anoikis, died in significant numbers in the presence of ABT-737.

Click to enlarge
Rating
Source J Biol Chem, 2010, 285, 19919-19920. ABT-737 purchased from Selleck
Method Cell Viability
Cell Lines INS-1E cells
Concentrations 10 μM
Incubation Time 24 h
Results Knockdown of PUMA partially prevented the proapoptotic action of ABT-737.

Click to enlarge
Rating
Source Apoptosis, 2010, 15, 1256-1269. ABT-737 purchased from Selleck
Method MTT assay
Cell Lines CCRF-CEM cells
Concentrations 10 μM
Incubation Time 24 h
Results Co-treatment of AY4 or TRAIL with a subtoxic dosage of ABT-737 (10 μM) showed reasonably increased cell death-inducing efficiency in CCRF-CEM cells by the additive effects of the two agents, compared with those of the single agent alone.The combinations of SAHA (1 μM) or VPA (1 mM) with ABT-737 (10 μM) also showed only additively enhanced cytotoxicity by the two agents. However, the presence of ABT-737 did not further potentiate the synergistic cytotoxicity induced by the combined treatment of AY4 or TRAIL with either SAHA or VPA.

Click to enlarge
Rating
Source Cancer Chemoth Pharm, 2011, 67, 557-567. ABT-737 purchased from Selleck
Method Crystal violet assay
Cell Lines TFK-1 cell/EGI-1 cell
Concentrations 1-40 μM
Incubation Time 72 h
Results ABT-737 potently inhibited the survival of cholangiocarcinoma cells only at high concentrations.

Click to enlarge
Rating
Source Cancer Chemoth Pharm, 2011, 67, 557-567. ABT-737 purchased from Selleck
Method Western blot
Cell Lines TFK-1 cell, EGI-1 cell
Concentrations 1-50 μM
Incubation Time 72 h
Results Combination experiments using drug concentrations close to IC50 (15 μM ZOL and 3 μM ABT-737 in EGI-1 cells; 30 μM ZOL and 10 μM ABT-737 in TFK-1 cells) were performed. The above-mentioned molecules when used as single agent at the same concentration determined moderate modification of proliferation pattern.

Click to enlarge
Rating
Source Exp Hematol , 2010, 38, 908-921. ABT-737 purchased from Selleck
Method Analysis of cell cycle and apoptosis
Cell Lines TF-1 cells
Concentrations 3 μM
Incubation Time 72 h
Results Bcl2 ablation using small molecule inhibitor ABT737 induced apoptosis in TF-1 cells in suspension and cocultures with MS5 stroma cells. We also show that the combination of two reagents, ABT737 and BIO, both downregulating Bcl2 in TF-1 cells, is more efficient than the effect of each single reagent used at the same dose.

Click to enlarge
Rating
Source Biochem Biophys Res Commun, 2012, 408, 344-9. ABT-737 purchased from Selleck
Method Flow cytometry
Cell Lines MDCKII wild type cells/MDR1 cells
Concentrations 50 nM
Incubation Time 24 h
Results MDCKII cells transfected with MDR1 showed significantly less apoptosis inducedby ABT-737 (Fig. C) and ABT-263 (Fig. D) than wild type cells.

Click to enlarge
Rating
Source Biochem Biophys Res Commun, 2013, 408, 344-9. ABT-737 purchased from Selleck
Method flow cytometry analysis/Annexin-V staining
Cell Lines Breast cancer cell lines
Concentrations 1 μM
Incubation Time 48 h
Results combined treatment of breast cancer cell lines with a suboptimal concentration (that is, 8 μM GSIXII and 1 μM ABT-737) strongly synergized to induce cell death (Figure A). The GSIXII and ABT-737 combination led to inhibition of mammosphere formation in both MCF7 and BT549 cell lines (Figure B ). The SAHM1 a nd ABT-737 combinational so decreased mammosphere formation (Figure C).

Click to enlarge
Rating
Source Dr. Arnim Weber of Medizinische Mikrobiologie und Hygiene Universitatsklinikum Freiburg. ABT-737 purchased from Selleck
Method
Cell Lines
Concentrations 1 μM
Incubation Time 24 h
Results

Click to enlarge
Rating
Source , Dr. Zhang of Tianjin Medical University. ABT-737 purchased from Selleck
Method Hoechst staining
Cell Lines MDB-MA-231 cells
Concentrations 100 nM
Incubation Time
Results

文献中の引用 (85)

技術サポート&よくある質問(FAQ)

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

電話番号: +1-832-582-8158 Ext:3月曜日〜金曜日 9:00 AM–5:00 PM (米国中部標準時)

他の質問がある場合は、お気軽くお問合せください。

* 必須

Related Bcl-2 阻害剤

  • A-1210477

    A-1210477 is a potent and selective MCL-1 inhibitor with Ki and IC50 of 0.454 nM and 26.2 nM, respectively, >100-fold selectivity over other Bcl-2 family members.

  • MI-773 (SAR405838)

    MI-773 (SAR405838) is an orally available MDM2 antagonist with Ki of 0.88 nM. Phase 1.

  • ABT-263 (Navitoclax)

    ABT-263(Navitoclax)は、 Bcl-xLBcl-2Bcl-w の強力な阻害剤で、Kiがそれぞれ ≤ 0.5 nM、≤1 nM 、≤ 1 nMです。

  • Venetoclax (ABT-199, GDC-0199)

    Venetoclax (ABT-199, GDC-0199) is a Bcl-2-selective inhibitor with Kiof < 0.010 nM.

    Features:Re-engineered version of ABT-263 (Navitoclax).

  • UMI-77

    UMI-77 is a selective Mcl-1 inhibitor with Ki of 490 nM, showing selectivity over other members of Bcl-2 family.

  • Obatoclax Mesylate (GX15-070)

    Obatoclax Mesylate (GX15-070)は Bcl-2 を抑制して、 Kiが0.22 μMになる.

    Features:Potential 1st-in-class small molecule antagonist of Bcl-2 designed to inhibit all relevant Bcl-2 family members, including Mcl-1.

  • TW-37

    TW-37は、組み換え型Bcl-2(Bcl-xLとMcl-1)への新しい非ペプチド阻害剤で、Ki がそれぞれ 0.29 μM、1.11 μM、0.26 μMです。

  • Sabutoclax

    Sabutoclax is a pan-Bcl-2 inhibitor, including Bcl-xL, Bcl-2, Mcl-1 and Bfl-1 with IC50 of 0.31 μM, 0.32 μM, 0.20 μM and 0.62 μM, respectively.

  • AT101

    AT-101は、反アポトーシスのBcl-2 の強力な阻害剤であることを知られて、模倣のBH3家族です。

最近チェックしたアイテム

Tags: ABT-737を買う | ABT-737供給者 | ABT-737を購入する | ABT-737費用 | ABT-737生産者 | オーダーABT-737 | ABT-737代理店
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
お問い合わせ